PeriphaGen, founded with a mission to revolutionize the treatment of neurologic disorders, is a biopharmaceutical company specializing in neuronal gene therapies. The company focuses on developing first-in-class gene delivery products using herpes simplex virus type I (HSV-1) vectors to target neurons directly. Their primary areas of interest include neuropathic pain, neuropathy, and neuronal regeneration, addressing significant unmet medical needs in these domains.
Notable figures associated with PeriphaGen include experts in virology and gene therapy, contributing to their innovative approach. The company has achieved significant milestones in developing HSV-1 vectors, showcasing their potential in treating nervous system diseases. PeriphaGen's impact lies in its pioneering methods and commitment to advancing therapeutic options for neurologic conditions, positioning it as a leader in the biopharmaceutical industry.
